Antiseizure Drug Pharmacology in the ICU

Antiseizure Drug Pharmacology in the ICU

Acute seizures and status epilepticus in the neuro-ICU demand aggressive, protocolized intravenous pharmacotherapy. Seizures dramatically escalate cerebral metabolic rate of oxygen ($CMRO_2$), exhaust cellular glucose and adenosine triphosphate ($ATP$), provoke massive lactic acidosis, drive acute intracranial pressure ($ICP$) surges, and induce excitotoxic neuronal necrosis through sustained glutamate release and intracellular calcium flooding. Selecting the appropriate antiseizure medication ($ASM$) requires thorough knowledge of loading paradigms, protein-binding nuances, metabolic interactions, and unique organ toxicities.

First-Line Parenteral Antiseizure Medications

ICU Antiseizure Drug Classification & Mechanisms
├── Synaptic Vesicle Glycoprotein 2A (SV2A) Ligands
│   ├── Levetiracetam: 60 mg/kg load, renally cleared, no CYP interactions, neuropsychiatric side effects
│   └── Brivaracetam: Higher SV2A affinity, faster brain entry, non-CYP hydrolysis and CYP2C19-mediated hydroxylation, lower irritability
├── Voltage-Gated Sodium Channel Modulators
│   ├── Fosphenytoin: Fast inactivation blocker, 20 mg PE/kg load, non-linear kinetics, Sheiner-Tozer correction
│   └── Lacosamide: Slow inactivation enhancer, 200-400 mg load, minimal interactions, PR prolongation / AV block
└── Multimodal Neurotransmitter Modulator
    └── Sodium Valproate: GABA enhancer, T-type Ca2+ / Na+ blocker, hyperammonemia (VHE), carbapenem interaction

Levetiracetam

• Mechanism: Binds stereoselectively to synaptic vesicle protein 2A ($SV2A$), an integral transmembrane vesicle glycoprotein. By modulating SV2A, it inhibits calcium-dependent exocytosis of excitatory neurotransmitters (primarily glutamate) without directly interfering with basal synaptic transmission.
• ICU Dosing & Kinetics:
  • Loading Dose: $60\text{ mg/kg}$ IV (maximum $4500\text{ mg}$) infused over 10 to 15 minutes. In status epilepticus, the established randomized ESETT trial confirmed the safety and efficacy of high-dose loading ($60\text{ mg/kg}$).
  • Maintenance: $1000\text{ to }1500\text{ mg}$ IV every 12 hours (adjusted for renal clearance).
  • Elimination: $66\%$ excreted unchanged in urine via glomerular filtration; $24\%$ undergoes non-hepatic enzymatic hydrolysis of the acetamide group into an inactive carboxylic acid metabolite ($ucb\text{ L057}$). It has low plasma protein binding (less than 10%) and exhibits no hepatic CYP450 interactions.
  • Renal Replacement Therapy: Highly cleared by hemodialysis ($50\%$ removed per 4-hour session); a supplemental dose is selected for the dialysis regimen; the adult label recommends 250–500 mg after conventional hemodialysis.
• Adverse Effects: Somnolence, dizziness, and prominent neuropsychiatric toxicity ("levetiracetam rage": agitation, irritability, emotional lability, depression, and acute psychosis). In neuro-ICU patients exhibiting unprovoked agitation or delirium, levetiracetam toxicity should always be considered.

Fosphenytoin

• Mechanism: Fosphenytoin is a water-soluble disodium phosphate ester prodrug of phenytoin. Following intravenous administration, blood and vascular endothelial alkaline phosphatases rapidly cleave the phosphate ester group ($t_{1/2\text{ conversion}} \approx 8\text{ to }15\text{ minutes}$), liberating active phenytoin. Phenytoin selectively binds to and stabilizes the inactive state of voltage-gated sodium channels, prolonging their inactivation and preventing repetitive, high-frequency neuronal firing.
• ICU Dosing:
  • Dosed exclusively in Phenytoin Sodium Equivalents ($PE$) to avoid dosing conversion errors ($1.5\text{ mg}$ fosphenytoin $= 1.0\text{ mg PE} = 1.0\text{ mg}$ phenytoin sodium).
  • Loading Dose: $20\text{ mg PE/kg}$ IV.
  • Infusion Rate: Up to $150\text{ mg PE/min}$ (three times faster than parenteral phenytoin's maximum rate of $50\text{ mg/min}$).
• Pharmacokinetics & Therapeutic Drug Monitoring:
  • Phenytoin exhibits non-linear, capacity-limited Michaelis-Menten elimination kinetics mediated by hepatic CYP2C9 and CYP2C19. Once hepatic enzymes become saturated within therapeutic concentrations, small dose increases cause disproportionate spikes in serum concentrations.
  • Target Levels: Total phenytoin $10\text{ to }20\text{ }\mu\text{g/mL}$; Free (unbound) phenytoin $1.0\text{ to }2.0\text{ }\mu\text{g/mL}$.
  • Protein Binding & The Sheiner-Tozer Equation: Phenytoin is $90\%$ bound to serum albumin. In critical illness, hypoalbuminemia and uremic toxin displacement increase the unbound (biologically active) free fraction. When albumin is depressed, the measured total phenytoin level appears falsely subtherapeutic while the active free level is therapeutic or toxic. The Sheiner-Tozer equation calculates adjusted total concentration:

*(In renal failure with creatinine clearance $< 20\text{ mL/min}$, the denominator constant shifts: $0.1 \times \text{Albumin} + 0.1$). Direct measurement of free phenytoin is the diagnostic gold standard.

• Adverse Effects: Cardiac arrhythmias, PR and QT prolongation, and hypotension driven by rapid sodium channel blockade. Fosphenytoin has an alkaline $pH$ ($8.6\text{--}9.0$), lower than parenteral phenytoin and lacks propylene glycol diluent, reducing local tissue toxicity, although purple glove syndrome and serious local injury remain possible caused by conventional parenteral phenytoin ($pH\ 12$).

Sodium Valproate

• Mechanism: Multi-mechanistic action: increases brain gamma-aminobutyric acid ($GABA$) levels by inhibiting GABA transaminase ($GABA\text{-}T$) and succinic semialdehyde dehydrogenase ($SSADH$), blocks voltage-gated sodium channels, and attenuates low-threshold T-type calcium currents in thalamic neurons.
• ICU Dosing: Loading dose of $40\text{ mg/kg}$ IV (maximum $3000\text{ mg}$) infused at $3\text{ to }6\text{ mg/kg/min}$; maintenance $15\text{ to }30\text{ mg/kg/day}$ divided every 8 hours. Target serum trough: $50\text{ to }100\text{ }\mu\text{g/mL}$ (up to $120\text{ }\mu\text{g/mL}$ in refractory status).
• Complications & Black-Box Warnings:
  • Valproate-Induced Hyperammonemic Encephalopathy (VHE): Valproic acid inhibits carbamoyl phosphate synthetase I ($CPS\text{-}I$) in the urea cycle and depletes mitochondrial carnitine. Patients develop acute lethargy, cognitive slowing, asterixis, and paradoxical seizure worsening. VHE occurs in the presence of completely normal transaminases (AST/ALT) and therapeutic valproate levels! Treatment: immediate cessation of valproate and administration of intravenous L-carnitine (specialist-directed regimens commonly use 100 mg/kg up to 6 g initially, then 50 mg/kg up to 3 g every eight hours; adjust to toxicity guidance).
  • Hematologic & Visceral Toxicity: Dose-dependent thrombocytopenia (especially at troughs $> 100\text{ }\mu\text{g/mL}$), acute necrotizing pancreatitis, and idiosyncratic fulminant hepatic failure.

Lacosamide

• Mechanism: Selectively enhances slow inactivation of voltage-gated sodium channels, in contrast to phenytoin, carbamazepine, and lamotrigine which primarily modulate fast inactivation. By promoting slow inactivation, lacosamide selectively dampens chronically depolarized, hyper-excitable epileptic neurons without disrupting physiologic basal neurotransmission.

• ICU Dosing & Profile: Loading dose $200\text{ to }400\text{ mg}$ IV infused over 15 minutes; maintenance $100\text{ to }200\text{ mg}$ IV every 12 hours. Negligible protein binding ($< 15\%$), low CYP interaction profile, and excreted $95\%$ by kidneys ($40\%$ unchanged).

• Adverse Effects: Dose-dependent PR interval prolongation, second- or third-degree AV block, and syncope. Baseline 12-lead ECG and telemetry monitoring are mandatory, especially in patients with pre-existing conduction disease or concurrent nodal-blocking medications.

• Clinical profile: IV brivaracetam is used in selected acute seizure settings, with status use and loading regimens guided by specialist protocols. Maintenance and hepatic adjustments follow the product information. Some observational switching studies suggest improved behavioral tolerability compared with levetiracetam, but there is no universally validated 1:10 equivalent conversion or guarantee that psychiatric adverse effects will disappear.